The figures published by altRx are not derived from clinical trials or peer-reviewed studies and are representative of altRx patient experience only
LM: Formal analysis, Writing review & editing
The specific cancer type that prompted the FDA warning represents a tiny fraction of an already uncommon outcome
2025: Outsourcing Facilities Association (OFA) files federal lawsuits challenging FDAs shortage resolution determinations
Timing: Optimal dosing times include upon waking (fasted), post-workout, and before bed
Document review Request current COA, HPLC chromatogram, MS identity support, SDS, storage notes, salt or counter-ion context, and batch-specific label details before approval